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Abstract
The Burkholderia cepacia complex (Bcc) is a group of closely related bacterial species that 
emerged in the 1980s as the etiological agents of severe and often lethal  respiratory 
­infections­among­cystic­fibrosis­ (CF)­patients.­After­several­outbreaks­ in­CF­centers­ in­
Europe­ and­North­America,­ segregation­measures­were­ introduced­ to­ avoid­ patient-
to-patient­ transmission.­Presently,­ the­prevalence­of­Bcc­ infections­among­CF­patients­
worldwide­is­below­5%­in­the­majority­of­CF­centers,­although­exceptions­are­registered­
in­ some­ European­ countries.­ Infections­ by­ these­ pathogens­ remain­ problematic­ due­
to­ the­ high­ resistance­ to­ antimicrobials,­ the­ easy­ patient-to-patient­ transmission,­ and­









The Burkholderia cepacia complex (hereafter referred to as Bcc) is a group of closely related 
­bacteria­that­emerged­in­the­1980s­as­problematic­pathogens­to­cystic­fibrosis­(CF)­patients­[1].­
Infections­by­Bcc­are­particularly­feared­due­to­(1)­the­easy­patient-to-patient­­transmission­of­
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Bcc species Genome sequence availability Reference
B. ambifaria 4­complete­genomes­(strains­AMMD,­MC40-6,­MEX-5,­IOP-120) [8]
B. anthina In­progress [9]








B. contaminans 1­complete­genome­(strain­MS14) [12]
B. diffusa In­progress [10]
B. dolosa 1­complete­genome­(strain­AU0158) [13]
B. lata 1­complete­genome­(strain­383) [12]
B. latens In­progress [10]
B. metallica No information [10]
B. multivorans 3­complete­genomes­(ATCC17616,­ATCC­BAA-247,­DDS­15A-1) [5]
B. pseudomultivorans In­progress [14]
B. pyrrocinia 1­complete­genome­(strain­DSM­10685) [9]
B. seminalis In­progress [10]
B. stabilis No information [15]
B. stagnalis In­progress [16]
B. territorii In­progress [16]
B. ubonensis 1­complete­genome­(strain­MSMB22) [17]
B. vietnamiensis 3­complete­genomes­(strains­G4,­LMG10929,­WPB) [18]
Databases­were­assessed­by­the­end­of­July­2016.
Table 1. Burkholderia cepacia­complex­species­names­and­genome­sequence­availability­ in­the­databases­Burkholderia­
Genome­DB­and­Integrated­Microbial­Genomes­&­Microbiomes­[6,­7].
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2. Evolving epidemiology of Bcc infections
All­ Bcc­ species­ are­ virtually­ potential­ pathogens­ to­ CF­ patients.­ However,­ epidemiology­
­studies­ have­ shown­ an­ uneven­ geographical­ and­ regional­ distribution­ of­ clinical­ ­isolates­
among­ the­ Bcc­ species,­ with­ the­ predominance­ of­ Burkholderia cenocepacia,­ followed­ by­
Burkholderia multivorans.­ Early­ studies­performed­during­ the­ 1980s­ and­ 1990s­have­ shown­
that­in­addition­to­cases­of­chronic­infection­due­to­specific­strains,­many­outbreaks­reported­
in­Europe­and­North­America­were­due­ to­ the­ spread­of­particularly­virulent­ strains­ that­
­easily­disseminated­within­a­given­CF­center­[1].­Although­the­environment­is­thought­to­be­
the­natural­reservoir­of­these­strains,­a­definitive­proof­is­still­lacking.
A­ few­ particularly­ epidemic­ strains­ became­ notorious­ for­ the­ worst­ reasons.­ Perhaps,­
the­best-known­ strain­ is­ the­Edinburgh-Toronto­ lineage­also­known­as­ the­ET12­ clone,­ an­
­intercontinental­ clone­ responsible­ for­ several­ infections­ and­ fatalities­ in­ CF­ centers­ in­ the­
UK­ and­ Canada­ [19].­ The­ best-known­ representative­ strain­ of­ this­ highly­ transmissible­
clone is the B. cenocepacia­J2315­strain,­the­first­Bcc­strain­with­its­genome­sequence­publicly­
 available (Table 1)­and­one­of­the­best­studied­Bcc­strains­[20].­Another­example­of­a­strain­
that­ ­disseminated­within­ centers­ and­ even­ among­ centers­ is­ the­ PHDC­ strain.­ The­ strain,­
­responsible­for­almost­20%­prevalence­in­one­CF­center­in­the­USA,­was­later­found­in­another­
CF­center,­where­an­ increase­ in­Bcc­prevalence­was­experienced.­The­dissemination­of­ the­
strain­was­ associated­with­ the­ transfer­ of­ an­ infected­patient­ from­ the­ initial­ center­ to­ the­
second­one­[21].­A­later­study­by­Coenye­et­al.­[22]­showed­that­the­PHDC­strain­was­also­
present­in­European­patients­(namely­in­France,­Italy,­and­the­UK),­concluding­that­the­PHDC­
strain­was­ the­second-identified­Bcc­ transatlantic­ clone.­ Interestingly,­both­ intercontinental­
clones belong to the B. cenocepacia­­species,­although­the­ET12­belongs­to­subgroup­IIIA­and­the­
PHDC­belongs­to­subgroup­IIIB.­The­B. cenocepacia species includes other clones that spread 
among­CF­centers,­namely­the­Midwest­American­clone­and­the­CZI­Czech­epidemic­clone­












demiology.­B. multivorans­ emerged­ as­ the­dominant­ species­ in­ France­ by­ 2004­ and­ as­ the­
second­most­important­species­in­the­USA­[31,­32].­Recent­reports­also­indicate­Burkholderia 
contaminans­ as­ an­ emerging­ Bcc­ species­ associated­with­ CF­ infections.­ Early­ reports­ of­ a­
high­incidence­of­the­species­among­CF­patients­came­from­Portugal­and­Argentina­[33–35].­
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Interestingly,­in­the­case­of­the­Portuguese­CF­population,­two­B. contaminans clones infecting 
CF­patients­were­found­as­ indistinguishable­ from­two­B. contaminans strains isolated from 




dominant species B. cenocepacia and B. multivorans­ [37].­ The­ emergence­ of­B. contaminans 
among­Spanish­CF­patients­was­hypothesized­to­be­due­to­unspecified­ecological­advantages­
that­ enable­ the­ species­ to­ increase­ its­presence­ in­hospitals­ or­ in­ the­ environment­ [37].­ In­
the­case­of­Swiss­CF-patients,­B. cenocepacia­was­the­most­frequently­isolated­species­in­the­
period­1998–2013,­but­B. multivorans and B. contaminans emerged during the last years of the 
study­period­[38].­A­30-year­study­of­Bcc­infections­among­CF­patients­from­British­Columbia­
(Canada)­evidenced­a­major­impact­of­segregation­measures­in­Bcc­epidemiology;­while­B. 
cenocepacia­was­dominant­before­ the­ introduction­of­ these­measures,­B. multivorans strains 
became­dominant­after­implementation­of­novel­infection­control­measures­in­1995­[39].­This­
study and others highlight the impact of infection control measures on Bcc species recovered 
from­CF­patients.­It­is­now­apparent­that­while­epidemic­B. cenocepacia strains dominated in 
early­years,­nonclonal­B. multivorans and B. contaminans­strains­are­emerging.
3. Bcc virulence factors and traits













3.1. Alternative sigma factors
RpoE­and­RpoN­are­two­alternative­sigma­factors­involved­in­the­regulation­of­the­ability­of­
intracellular B. cenocepacia­ to­delay­phagolysosomal­ fusion­ in­murine­macrophages­ [44,­ 45].­
RpoE­is­the­extra-cytoplasmic­stress­response­regulator­required­by­B. cenocepacia­to­grow­under­
conditions­of­high­osmolarity­and­high­ temperature­ [44].­RpoN,­or­ sigma­ factor­σ54,­ is­best­
known­for­its­involvement­in­nitrogen-related­gene­regulation.­In­B. cenocepacia,­σ54 is involved 
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in­motility­and­biofilm­formation­[45].­Results­from­the­mapping­of­σ54 regulon and the charac-







3.2. Lipopolysaccharides and extracellular polysaccharides
One­of­the­central­components­of­the­outer­membrane­in­Gram-negative­bacteria­is­the­lipop-
olysaccharide­(LPS),­a­complex­molecule­composed­by­the­lipid­A,­the­core­oligosaccharide,­
and­ the­O-antigen­moieties­ (reviewed­ in­Ref.­ [48]).­The­genes­ involved­ in­LPS­production­
by B. cenocepacia­are­located­in­chromosome­I,­organized­in­three­main­clusters,­one­for­each­
LPS­ component­ (lipid­A:­ BCAL1929 to BCAL1935;­ core:­ BCAL2402 to BCAL2408;­ O­ anti-
gen:­BCAL3110 to BCAL3125)­ together­with­additional­genes­ encoding­ sugar­ ­modification­
enzymes­[49,­50].­Bcc­bacteria­LPS­differs­from­other­Gram-negative­­bacteria­LPS­due­to­the­
complete­ lack­of­negatively­charged­residues­and­the­presence­of­ the­heterodimeric­disac-












an interruption in the wbcE­gene-encoding­BCAL­3125­[56].­The­expression­of­O-antigen­by­
Bcc­ strains­was­demonstrated­ to­ reduce­phagocytosis­by­macrophages­without­ interfering­
with­the­intracellular­survival­of­bacteria­[56].
The­production­of­exopolysaccharides­(EPSs)­was­described­for­several­Burkholderia­species.­EPS­






[64–67].­As­a­result­of­a­frameshift­mutation­in­the­bceB gene (BCAM0856) encoding a putative 






Bcc­ bacteria­ were­ found­ to­ persist­ in­ biofilms­ in vitro.­ Biofilm­ formation­ and­maturation­
depend­on­many­factors,­including­EPS­production,­motility,­iron­availability,­and­­multiple­
gene­ regulatory­ systems,­ such­ as­ quorum­ sensing,­ alternative­ sigma­ factors,­ or­ global­
­regulators­such­as­the­ShvR­and­AtsR­[45,­58,­68–73].­In­addition,­Bcc­can­form­small­colony­














Quorum sensing is a mode of regulation of gene expression that is dependent on the  density 
of­ the­ bacterial­ population.­ Bcc­ bacteria­ have­ at­ least­ four­ quorum­ sensing­ systems.­ The­
CepIR­quorum­sensing­system­is­homologous­to­the­LuxIR­system­of­Vibrio fischeri­(reviewed­
in­Ref.­ [79]).­ The­CepIR­ system­positively­ regulates­ the­virulence­of­B. cenocepacia­ toward­






negatively regulated siderophore synthesis and the positively regulated expression of the 
genes­­encoding­zinc­metalloproteases­(Zmps),­swarming­motility­and­biofilm­formation,­all­
thought­to­have­an­impact­when­the­bacterium­is­infecting­the­CF­patient­[71,­80,­86,­87].
3.5. Protein secretion systems
Both­ Gram-negative­ and­ positive­ bacteria­ use­ protein­ secretion­ systems­ to­ secrete­ toxins­
or­other­proteins,­either­directly­into­the­environment­or­into­host­cells.­These­systems­are­











role in intracellular survival of B. cenocepacia­[94].
Four­ type­V­secretion­systems­are­encoded­within­ the­genome­of­B. cenocepacia­ J2315­ [49].­
Proteins­ transported­ by­ this­ type­ of­ transporters­ contain­ pertactin­ and­ hemagglutinin­
domains­and­are­thought­to­play­a­role­in­bacterial­adhesion­[49].
B. cenocepacia­ also­ encodes­ a­ T6SS,­ which­ was­ shown­ to­ affect­ the­ actin­ cytoskeleton­ of­
 macrophages and the assembly of the reduced nicotinamide adenine dinucelotide phosphate 









allow­the­secretion­of­several­hydrolytic­enzymes­and­toxins­[98].­Table 2 summarizes and 





appears to be the most important and abundant siderophore produced by B. cenocepacia 
strains­ [123,­ 124].­ The­ pathways­ and­ regulatory­ mechanisms­ of­ ornibactin­ synthesis­ and­
uptake­ are­ relatively­ well­ known­ [87,­ 125–127].­ The­ requirement­ of­ this­ siderophore­ for­
B.  cenocepacia­virulence­was­demonstrated­in­different­infection­models,­including­the­rat­agar­
bead,­G.  mellonella, and C. elegans­[82,­125,­127].
The­competition­for­available­iron­by­Bcc­bacteria­and­other­CF­lung­colonizing­organisms­
such as P. aeruginosa­was­reported­to­occur­in­the­CF­lung,­although­it­is­not­completely­clear­
how­Bcc­organisms­acquire­iron­from­host­proteins­[128,­129].
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3.7. Resistance to antimicrobials
Difficulties­in­eradicating­Bcc­infections­mainly­result­from­their­intrinsic­resistance­to­­multiple­
antibiotics,­including­polymyxins,­aminoglycosides,­and­most­β-lactams.­In­­addition,­these­bac-




enzymes,­dihydrofolate­ reductase),­alteration­of­drug­ targets,­ integrons,­ cell­wall­ imperme-
ability,­and­active­efflux­pumps­[88,­133–140].­However,­major­contributions­to­intrinsic­and­
acquired­multidrug­resistance­by­Bcc­seem­to­be­due­to­efflux­pumps­of­the­resistance­nod-
ulation­cell­division­ (RND)­ family.­ In­ fact,­ the­B. cenocepacia­ J2315­genome­encodes­at­ least­
16­efflux­systems­of­the­RND­family­[141].­At­least­six­of­these­RND­efflux­pumps­were­impli-
cated­in­drug­resistance—RND-1,­RND-3,­RND-4,­RND-8,­RND-9,­and­RND-10­[138–140,­142,­









































Table 2. Summary­of­secretion­systems­from­Bcc­and­the­respective­counterparts­from­the­CF­major­pathogen­P. aeruginosa.














More­ recently,­ flagellin­ expression­ and­ flagellar­morphology­ of­B. cenocepacia­ grown­ in­ a­
medium­mimicking­the­CF­sputum­was­analyzed­[147].­Those­nutritional­conditions­led­to­
increased­motility­and­flagellin­expression,­by­inducing­the­synthesis­of­multiple­flagella­on­
the cell surface of B. cenocepacia­K56-2­[147].­A­link­between­the­loss­of­bacterial­motility­and­
the­development­of­the­cepacia­syndrome­was­recently­established­based­on­a­transcriptomics­











to­heat-killed­bacteria­ that­ ended­up­ in­phagolysosomes­with­ a­pH­of­ 4.5,­BcCVs­did­not­
acidify­normally­maintaining­a­luminal­pH­around­6.4­[94].­This­ability­of­B. cenocepacia to 
alter­the­acidification­of­the­vacuole­seems­to­be­correlated­with­the­delay­in­recruitment­or­
assembly­on­ the­BcCV­membrane­of­both­ the­16-kDa­subunit­of­ the­phagosomal­vacuolar­
ATPase­(vATPase)­and­the­NADPH­phagocyte­oxidase­[96,­151].­In­contrast,­Al-Khodor­and­












have also been performed in Cystic­fibrosis­transmembrane conductance­regulator­(CFTR)-
defective­macrophages.­ Remarkably,­ the­ delayed­maturation­ arresting­ of­ BcCV's­ is­more­
exaggerated­in­CFTR-defective­macrophages­than­in­normal­macrophages­and­is­specific­to­
live B. cenocepacia­[153].­Although­it­is­not­clear­how­the­CFTR­defect­enhances­the­B. ceno-
cepacia­ intracellular­ survival,­ there­ is­ evidence­of­a­ link­between­ the­defective­CFTR­with­
autophagy­deficiency­and­decreased­clearance­of­protein­aggregates­and­inflammation­[154].­
The­elucidation­of­these­survival­details,­especially­the­ability­of­B. cenocepacia to synergize 
with­the­CFTR­defect­and­its­consequences­on­the­mechanism­of­autophagy­will­provide­new­
avenues­to­explore­novel­therapeutic­approaches­for­CF­patients­[155].
4. Toward a vaccine to prevent Bcc infections
No­objective­ guidelines­ for­ eradication­ strategies­ are­ available­ for­ Bcc­ infections,­ as­ these­
pathogens­ are­ intrinsically­ resistant­ to­ the­majority­ of­ the­ clinical­ available­ antimicrobials­
[156].­Currently,­no­immunotherapeutic­strategy­to­protect­CF­patients­from­Bcc­infections­
is­available.­Several­studies­on­the­ immune­response­elicited­by­Bcc­species­ in­CF­patients­
have­ been­ performed;­ however,­ they­ are­ challenging­due­ to­ the­ ability­ of­ this­ bacteria­ to­
modulate and overcome the host immune responses and the ability to survive intracellularly 
in­­phagocytes­and­epithelial­cells­[157,­158].
An­ important­aspect­ to­consider­during­vaccine­design­ is­ the­optimal­balance­of­Th1­and­
Th2­responses­ required­ for­effective­pathogen­clearance.­For­example,­a­Th1­bias­elicits­a­
cell-mediated­response,­while­Th2­ induces­a­humoral­ immune­response­ [159].­ In­ the­case­
of­CF,­ their­ immune­phenotype­appears­ to­be­skewed­toward­Th2­responses­ [160].­ In­ the­
case­of­Bcc,­the­type­of­host­response­necessary­to­clear­the­pathogen­is­still­not­fully­under-
stood,­making­it­difficult­to­develop­a­protective­vaccine­(Table 3).­Recently,­BALB/c­mice­
­immunized­ ­intraperitoneally­with­ the­ proteins­ Linocin­ and­OmpW­ showed­ a­ significant­





Nonpurified­ outer­ membrane­ proteins­ (OMP)­ from­ B. multivorans,­ supplemented­ with­
the­ mucosal­ adjuvant­ adamantylamide­ dipeptide­ (AdDP)­ that­ promotes­ a­ robust­ Th2­
response,­ were­ tested­ for­ immunization­ of­ BALB/c­ mice­ [162].­ A­ statistically­ significant­
increase­in­IgG­and­in­mucosal­IgA­OMP-specific­antibodies­was­observed,­together­with­a­
 reduction of B. multivorans­burden­and­lung­pathology,­but­only­a­moderate­cross­protection­
to B.  cenocepacia­was­reported.­The­specificity­of­the­immune­response­was­found­to­be­against­


















model­ [164].­ In­ this­ study­by­Skurnik­and­colleagues­using­opsophagocytic­ assays,­ it­was­
observed­that­goat-raised­antibodies­against­PNAG­could­kill­Bcc­strains­(>80%)­of­the­B. ceno-
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cepacia,­Burkholderia dolosa and B. multivorans­species.­Furthermore,­bacterial­killing­was­found­
to­depend­of­the­presence­of­the­complement­[164].
Other­ proteins­ of­ putative­ immunogenic­ activity­ have­ been­ reported­ as­ potential­ vaccine­
­candidates.­However,­studies­in­a­Bcc­infection­animal­model­are­still­lacking­(Table 3).­One­
of­these­promising­antigens­is­the­OmpA-like­BCAL2958­protein­that­was­shown­to­be­highly­
conserved­ in­Bcc,­ to­elicit­ IgG­antibodies­ in­CF­patients­and­ to­elicit­an­ increase­of­TNFα,­
elastase,­NO,­and­MPO­in­neutrophils­[166].
Musson­and­colleagues­have­shown­that­T-cell­hybridomas­against­the­Burkholderia  pseudomallei 







effective­ in­preventing­Bcc­ infections.­With­ this­ aim,­ immunoproteomics­ approaches­have­
been­ performed.­ For­ instance,­Mariappan­ and­ colleagues­ identified­ 18­ immunogenic­ pro-
teins from culture supernatants of B. cepacia­that­reacted­with­mice­antibodies­raised­against­
inactivated B. cepacia­whole­ cells­ [167].­More­ recently,­ the­ analysis­ of­ the­ imunoproteome­























ginosa and Burkholderia cepacia.­Microbiol­Rev.­1996;­60:539-574.
[2]­ Isles­A,­Maclusky­ I,­Corey­M,­Gold­R,­Prober­C,­Fleming­P,­Levison­H.­Pseudomonas 










Lauwers­ S,­ Gillis­ M,­ Kersters­ K,­ Govan­ JR.­ Occurrence­ of­ multiple­ genomovars­ of­
Burkholderia cepacia­in­cystic­fibrosis­patients­and­proposal­of­Burkholderia multivorans­sp.­
nov.­Int­J­Syst­Bacteriol.­1997;­47:1188-1200.­DOI:10.1099/00207713-47-4-1188.




[8]­ Coenye­ T,­ Mahenthiralingam­ E,­ Henry­ D,­ LiPuma­ JJ,­ Laevens­ S,­ Gillis­ M,­ Speert­




JR,­Mahenthiralingam­E.­Burkholderia anthina­ sp.­nov.­and­Burkholderia pyrrocinia,­ two­
additional Burkholderia cepacia­complex­bacteria,­may­confound­results­of­new­molecular­






D,­Dowson­C,­Vandamme­P.­Burkholderia latens­ sp.­nov.,­Burkholderia diffusa­ sp.­nov.,­
Burkholderia arboris­sp.­nov.,­Burkholderia seminalis­sp.­nov.­and­Burkholderia metallica­sp.­






E,­ Speert­DP,­Dowson­C,­Vandamme­P.­ Taxon­K,­ a­ complex­within­ the­Burkholderia 
cepacia­complex,­comprises­at­least­two­novel­species,­Burkholderia contaminans­sp.­nov.­
and Burkholderia lata­sp.­nov.­ Int­ J­Syst­Evol­Microbiol.­2009;­59:102-111.­DOI:10.1099/
ijs.0.001123-0.
[13]­ Vermis­K,­Coenye­T,­LiPuma­JJ,­Mahenthiralingam­E,­Nelis­HJ,­Vandamme­P.­Proposal­
to accommodate Burkholderia cepacia­genomovar­VI­as­Burkholderia dolosa­sp.­nov.­Int­J­
Syst­Evol­Microbiol.­2004;­54:689-691.­DOI:10.1099/ijs.0.02888-0.
[14]­ Peeters­C,­Zlosnik­JE,­Spilker­T,­Hird­TJ,­LiPuma­JJ,­Vandamme­P.­Burkholderia pseudo-






[16]­ De­ Smet­ B,­Mayo­M,­ Peeters­ C,­ Zlosnik­ JE,­ Spilker­ T,­ Hird­ TJ,­ LiPuma­ JJ,­ Kidd­ TJ,­
Kaestli­M,­Ginther­JL,­Wagner­DM,­Keim­P,­Bell­SC,­Jacobs­JA,­Currie­BJ,­Vandamme­P.­
Burkholderia stagnalis­sp.­nov.­and­Burkholderia territorii­sp.­nov.,­two­novel­Burkholderia 
cepacia­ complex­ species­ from­ environmental­ and­ human­ sources.­ Int­ J­ Syst­ Evol­
Microbiol.­2015;­65:2265-2271.­DOI:10.1099/ijs.0.000251.
[17]­ Yabuuchi­ E,­ Kawamura­ Y,­ Ezaki­ T,­ Ikedo­M,­Dejsirilert­ S,­ Fujiwara­N,­Naka­ T.­ and­
Kobayashi­ K.­ Burkholderia ubonensis­ sp.­ nov.,­ L-arabinose-assimilating­ but­ different­
from Burkholderia thailandensis and Burkholderia vietnamiensis.­Microbiol­Immunol.­2000;­
44:307-317.­DOI:10.1111/j.1348-0421.2000.tb02500.x.
[18]­ Gillis­ M,­ Van­ TV,­ Bardin­ R,­ Goor­ M,­ Hebbar­ P,­ Willems­ A,­ Segers­ P,­ Kersters­ K,­
Heulin­ T,­ Fernandez­MP.­ Polyphasic­ taxonomy­ in­ the­ genus­Burkholderia leading to 
an amended description of the genus and proposition of Burkholderia vietnamiensis­sp.­
nov.­ for­N2-fixing­ isolates­ from­rice­ in­Vietnam.­ Int­ J­Syst­Bacteriol.­ 1995;­ 45:274-289.­DOI:10.1099/00207713-45-2-274.













demiology of Burkholderia cepacia­complex­infection­in­cystic­fibrosis.­J­Infect­Dis.­2002;­
185:1454-1462.­DOI:10.1086/340279.
[24]­ Drevinek­P,­Mahenthiralingam­E.­Burkholderia cenocepacia­in­cystic­fibrosis:­epidemiol-
ogy­ and­molecular­mechanisms­ of­ virulence.­ Clin­Microbiol­ Infect.­ 2010;­ 16:821-830.­
DOI:10.1111/j.1469-0691.2010.03237.x.
[25]­ Thomassen­ MJ,­ Demko­ CA,­ Klinger­ JD,­ Stern­ RC.­ Pseudomonas cepacia colonization 
among­ patients­ with­ cystic­ fibrosis.­ A­ new­ opportunist.­ Am­ Rev­ Respir­ Dis.­ 1985;­
131:791-796.­DOI:10.1164/arrd.1985.131.5.791.
[26]­ Whiteford­ML,­Wilkinson­JD,­McColl­JH,­et­al.­Outcome­of­Burkholderia (Pseudomonas) 
cepacia­colonisation­in­children­with­cystic­fibrosis­following­a­hospital­outbreak.­Thorax.­
1995:50;­1194-1198.­DOI:10.1136/thx.50.11.1194.
[27]­ Muhdi­ K,­ Edenborough­ FP,­ Gumery­ L,­ et­ al.­ Outcome­ for­ patients­ colonised­ with­
Burkholderia cepacia­ in­a­Birmingham­adult­cystic­fibrosis­clinic­and­the­end­of­an­epi-
demic.­Thorax.­1996;­51:374-377.­DOI:10.1136/thx.51.4.374.
[28]­ Lynch­ JP­ 3rd.­Burkholderia cepacia­ complex:­ impact­ on­ the­ cystic­ fibrosis­ lung­ lesion.­
Semin­Respir­Crit­Care­Med.­2009;­30:596-610.­DOI:10.1055/s-0029-1238918.






Species­distribution­and­ribotype­diversity­of­Burkholderia cepacia complex isolates from 
French­patients­with­cystic­fibrosis.­ J­Clin­Microbiol.­2004;­42:4824-4827.­DOI:10.1128/
JCM.42.10.4824-4827.2004.
Burkholderia cepacia Complex Infections Among Cystic Fibrosis Patients: Perspectives and Challenges
http://dx.doi.org/10.5772/67712
87
[32]­ Reik­R,­Spilker­T,­Lipuma­JJ.­Distribution­of­Burkholderia cepacia complex species among 
isolates­recovered­from­persons­with­or­without­cystic­fibrosis.­J­Clin­Microbiol.­2005;­
43:2926-2928.­DOI:10.1128/JCM.43.6.2926-2928.2005.
[33]­ Cunha­MV,­ Leitão­ JH,­ Mahenthiralingam­ E,­ Vandamme­ P,­ Lito­ L,­ Barreto­ C,­ et­ al.­
Molecular­ analysis­ of­ Burkholderia cepacia­ complex­ isolates­ from­ a­ Portuguese­ cystic­
fibrosis­ center:­ a­ 7-year­ study.­ J­ Clin­ Microbiol.­ 2003;­ 41(9):4113-4120.­ DOI:10.1128/
JCM.41.9.4113-4120.2003.








[36]­ Cunha­ MV,­ Pinto-de-Oliveira­ A,­ Meirinhos-Soares­ L,­ Salgado­ MJ,­ Melo-Cristino­ J,­
Correia­S,­Barreto­C,­Sá-Correia­I.­Exceptionally­high­representation­of­Burkholderia cepa-
cia among B. cepacia­complex­isolates­recovered­from­the­major­Portuguese­cystic­fibrosis­
center.­J­Clin­Microbiol.­2007;­45:1628-1633.­DOI:10.1128/JCM.00234-07.







Wilcox­P,­ Speert­DP.­Burkholderia­ species­ infections­ in­patients­with­ cystic­fibrosis­ in­




[41]­ Tomich­M,­Herfst­CA,­Golden­JW,­Mohr­CD.­Role­of­flagella­ in­host­cell­ invasion­by­
Burkholderia cepacia.­ Infect­ Immun.­ 2002;­ 70(4):1799-1806.­ DOI:10.1128/IAI.70.4.1799- 
1806.2002.
[42]­ Lefebre­M,­ Valvano­M.­ In­ vitro­ resistance­ of­Burkholderia cepacia complex isolates to 
reactive­oxygen­ species­ in­ relation­ to­ catalase­ and­ superoxide­dismutase­production.­
Microbiology.­2001;­147:97-109.­DOI:10.1099/00221287-147-1-97.
[43]­ Miethke­M,­Marahiel­MA.­ Siderophore-based­ ion­ acquisition­ and­ pathogen­ control.­
Microbiol­Mol­Biol­Rev.­2007;­71:413-451.­DOI:10.1128/MMBR.00012-07.
Progress in Understanding Cystic Fibrosis88




sigma­ factor­ for­ biofilm­ formation­ and­ intracellular­ trafficking­within­macrophages.­
Infect­Immun.­2008;­76:1059-1067.­DOI:10.1128/IAI.01167-07.
[46]­ Lardi­M,­Aguilar­C,­Pedrioli­A,­et­al.­σ(54)-dependent­response­to­nitrogen­limitation­
and virulence in Burkholderia cenocepacia­ strain­ H111.­Appl­ Environ­Microbiol.­ 2015;­
81:4077-4089.­DOI:10.1128/AEM.00694-15.
[47]­ Hunt­TA,­Kooi­C,­Sokol­PA,­Valvano­MA.­Identification­of­Burkholderia cenocepacia genes 
required­for­bacterial­survival­in­vivo.­Infect­Immun.­2004;­72(7):4010-4022.­DOI:10.1128/
IAI.72.7.4010-4022.2004.






inner­ core­ oligosaccharide­ is­ required­ for­ resistance­ of­ Burkholderia cenocepacia to 
­antimicrobial­peptides­and­bacterial­ survival­ in­vivo.­ J­Bacteriol.­ 2006;­188:2073-2080.­
DOI:10.1128/JB.188.6.2073-2080.2006.
[51]­ De­Soyza­A,­Silipo­A,­Lanzetta­R,­Govan­JR,­Molinaro­A.­Review:­chemical­and­­biological­
features of Burkholderia cepacia­ complex­ lipopolysaccharides.­ Innate­ Immun.­ 2008;­
14(3):127-144.­DOI:10.1177/1753425908093984.

























[59]­ Ferreira­ AS,­ Leitão­ JH,­ Silva­ IN,­ et­ al.­ Distribution­ of­ cepacian­ biosynthesis­ genes­






cal strains belonging to the Burkholderia cepacia­complex.­J­Cyst­Fibros.­2007;­6(2):145-152.­
DOI:10.1016/j.jcf.2006.06.004.
[62]­ Moreira­LM,­Videira­PA,­Sousa­SA,­Leitão­JH,­Cunha­M­V,­Sá-Correia­I.­Identification­
and physical organization of the gene cluster involved in the biosynthesis of Burkholderia 
cepacia­ complex­ exopolysaccharide.­Biochem­Biophys­Res­Commun.­ 2003;­ 312(2):323-
333.­DOI:10.1016/j.bbrc.2003.10.118.
[63]­ Chiarini­ L,­ Cescutti­ P,­ Drigo­ L,­ et­ al.­ Exopolysaccharides­ produced­ by­ Burkholderia 
cenocepacia­recA­lineages­IIIA­and­IIIB.­J­Cyst­Fibros.­2004;­3(3):165-172.­DOI:10.1016/j.
jcf.2004.04.004.
[64]­ Bylund­ J,­ Burgess­ LA,­ Cescutti­ P,­ Ernst­ RK,­ Speert­ DP.­ Exopolysaccharides­ from­








[67]­ Zlosnik­ JEA,­Hird­TJ,­ Fraenkel­MC,­Moreira­LM,­Henry­DA,­ Speert­DP.­Differential­
mucoid exopolysaccharide production by members of the Burkholderia cepacia­complex.­
J­Clin­Microbiol.­2008;­46:1470-1473.­DOI:10.1128/JCM.02273-07.
[68]­ Messiaen­A-S,­Nelis­H,­Coenye­T.­Investigating­the­role­of­matrix­components­in­pro-
tection of Burkholderia cepacia­complex­biofilms­against­tobramycin.­J­Cyst­Fibros.­2014;­
13:56-62.­DOI:10.1016/j.jcf.2013.07.004.
Progress in Understanding Cystic Fibrosis90
[69]­ Huber­B,­Riedel­K,­Köthe­M,­Givskov­M,­Molin­S,­Eberl­L.­Genetic­ analysis­of­ func-
tions­involved­in­the­late­stages­of­biofilm­development­in­Burkholderia cepacia­H111.­Mol­
Microbiol.­2002;­46(2):411-426.­DOI:10.1046/j.1365-2958.2002.03182.x.
[70]­ Berlutti­ F,­Morea­ C,­ Battistoni­A,­ et­ al.­ Iron­ availability­ influences­ aggregation,­ bio-



















susceptibility of Burkholderia cepacia­ complex­ organisms­ when­ grown­ planktonically­
or­ as­ biofilm­ in­ vitro.­ Eur­ J­Clin­Microbiol­ Infect­Dis.­ 2007;­ 26:213-216.­DOI:10.1007/
s10096-007-0256-x.
[77]­ Van­Acker­H,­Sass­A,­Bazzini­S,­et­al.­Biofilm-grown­Burkholderia cepacia complex cells 
survive­antibiotic­ treatment­by­avoiding­production­of­ reactive­oxygen­species.­PLoS­
One.­2013;­8:e58943.­DOI:10.1371/journal.pone.0058943.
[78]­ Murphy­MP,­Caraher­E.­Residence­in­biofilms­allows­Burkholderia cepacia complex (Bcc) 
bacteria­to­evade­the­antimicrobial­activities­of­neutrophil-like­dHL60­cells.­Pathog­Dis. 
2015;­73(8):ftv069.­DOI:­10.1093/femspd/ftv069.
[79]­ Venturi­ V,­ Friscina­ A,­ Bertani­ I,­ Devescovi­ G,­ Aguilar­ C.­ Quorum­ sensing­ in­ the­
Burkholderia cepacia­complex.­Res­Microbiol.­2004;­155(4):238-244.­DOI:10.1016/j.resmic. 
2004.01.006.
[80]­ Kooi­C,­ Subsin­B,­Chen­R,­ Pohorelic­ B,­ Sokol­ PA.­Burkholderia cenocepacia­ ZmpB­ is­ a­
broad-specificity­ zinc­ metalloprotease­ involved­ in­ virulence.­ Infect­ Immun.­ 2006;­
74(7):4083-4093.­DOI:10.1128/IAI.00297-06.




ing system contributes to the virulence of Burkholderia cenocepacia­respiratory­infections.­
Microbiology.­2003;­149(Pt­12):3649-3658.­DOI:10.1099/mic.0.26540-0.
[82]­ Uehlinger­S,­Schwager­S,­Bernier­SP,­et­al.­Identification­of­specific­and­universal­viru-
lence factors in Burkholderia cenocepacia­strains­by­using­multiple­infection­hosts.­Infect­
Immun.­2009;­77:4102-4110.­DOI:10.1128/IAI.00398-09.




[84]­ Baldwin­A,­Sokol­PA,­Parkhill­J,­Mahenthiralingam­E.­The­Burkholderia cepacia epidemic 
strain­marker­ is­part­of­a­novel­genomic­island­encoding­both­virulence­and­metabo-
lism-associated­genes­ in­Burkholderia cenocepacia.­ Infect­ Immun.­ 2004;­ 72(3):1537-1547.­
DOI:10.1128/IAI.72.3.1537-1547.2004.
[85]­ Subramoni­S,­Sokol­PA.­Quorum­sensing­systems­influence­Burkholderia cenocepacia viru-
lence.­Future­Microbiol.­2012;­7(12):1373-1387.­DOI:10.2217/fmb.12.118.
[86]­ Huber­B,­Riedel­K,­Hentzer­M,­et­ al.­The­ cep­quorum-sensing­ system­of­Burkholderia 


















utes to intracellular survival and replication of Burkholderia cenocepacia.­Infect­Immun.­
2008;­76:5447-5455.­DOI:10.1128/IAI.00451-08.
Progress in Understanding Cystic Fibrosis92
[93]­ Tomich­ M,­ Griffith­ A,­ Herfst­ CA,­ Burns­ JL,­ Mohr­ CD.­ Attenuated­ virulence­ of­ a­





[95]­ Flannagan­RS,­ Jaumouillé­V,­Huynh­KK,­ et­ al.­Burkholderia cenocepacia disrupts host 
cell­actin­cytoskeleton­by­inactivating­Rac­and­Cdc42.­Cell­Microbiol.­2012;­14:239-254.­
DOI:10.1111/j.1462-5822.2011.01715.x.
[96]­ Rosales-Reyes­R,­ Skeldon­AM,­Aubert­DF,­Valvano­MA.­The­Type­VI­ secretion­ sys-




by intracellular Burkholderia cenocepacia.­J­Immunol.­2012;­188:3469-3477.­DOI:10.4049/
jimmunol.1102272.
[98]­ Allan­ND,­Kooi­C,­Sokol­PA,­Beveridge­TJ.­Putative­virulence­factors­are­released­in­












[102]­ Olson­ JC,­Ohman­DE.­ Efficient­ production­ and­processing­ of­ elastase­ and­LasA­by­
Pseudomonas aeruginosa­ require­zinc­and­calcium­ions.­ J­Bacteriol.­1992;­174(12):4140-
4147.­http://www.ncbi.nlm.nih.gov/pmc/articles/PMC206126/.
[103]­ Cahan­R,­Axelrad­ I,­ Safrin­M,­Ohman­DE,­Kessler­E.­A­ secreted­aminopeptidase­of­
Pseudomonas aeruginosa:­ identification,­ primary­ structure,­ and­ relationship­ to­ other­
­aminopeptidases.­J­Biol­Chem.­2001;­276(47):43645-43652.­DOI:10.1074/jbc.M106950200.
[104]­ Engel­ LS,­Hill­ JM,­ Caballero­AR,­Green­ LC,­O'Callaghan­ RJ.­ Protease­ IV,­ a­ unique­
 extracellular protease and virulence factor from Pseudomonas aeruginosa.­J­Biol­Chem.­
1998;­273(27):16792-16797.­DOI:10.1074/jbc.273.27.16792.

















Biochemistry­ and­ Pharmacology.­ Berlin,­ Heidelberg:­ Springer­ Berlin­ Heidelberg;­
2005:79-92.­DOI:10.1007/s10254-004-0031-7.
[110]­ Yahr­TL,­Vallis­AJ,­Hancock­MK,­Barbieri­ JT,­Frank­DW.­ExoY,­an­adenylate­cyclase­






[113]­ Klockgether­ J,­Würdemann­D,­ Reva­O,­Wiehlmann­ L,­ Tümmler­ B.­Diversity­ of­ the­
abundant­ pKLC102/PAGI-2­ family­ of­ genomicislands­ in­ Pseudomonas aeruginosa.­ J­
Bacteriol.­2007;­189(6):2443-2459.­DOI:10.1128/JB.01688-06.
[114]­ Mikkelsen­H,­Hui­K,­Barraud­N,­Filloux­A.­The­pathogenicity­island­encoded­PvrSR/









involved­ in­ fimbrial­ assembly­ and­ TpsA­ secretion.­ EMBO­ J.­ 2008;­ 27(20):2669-2680.­
DOI:10.1038/emboj.2008.197.
Progress in Understanding Cystic Fibrosis94
[118]­ Faure­LM,­Garvis­S,­de­Bentzmann­S,­Bigot­S.­Characterization­of­a­novel­two-partner­








[121]­ Bomberger­ JM,­ MacEachran­ DP,­ Coutermarsh­ BA,­ Ye­ S,­ O'Toole­ GA,­ Stanton­ BA.­
Long-distance­delivery­of­bacterial­virulence­factors­by­Pseudomonas aeruginosa outer 





lates of Burkholderia cepacia.­Infect­Immun.­1998;­66:874-877.
[124]­ Agnoli­K,­Lowe­CA,­Farmer­KL,­Husnain­SI,­Thomas­MS.­The­ornibactin­biosynthesis­




synthesis in the virulence of Burkholderia cepacia:­ characterization­ of­ pvdA,­ the­ gene­
encoding­l-ornithine­N(5)-oxygenase.­Infect­Immun.­1999;­67(9):4443-4455.
[126]­ Sokol­PA,­Darling­P,­Lewenza­S,­Corbett­CR,­Kooi­CD.­Identification­of­a­siderophore­
receptor­ required­ for­ ferric­ ornibactin­ uptake­ in­Burkholderia cepacia.­ Infect­ Immun.­
2000;­68(12):6554-6560.
[127]­ Visser­MB,­Majumdar­S,­Hani­E,­Sokol­PA.­Importance­of­the­ornibactin­and­pyochelin­
siderophore transport systems in Burkholderia cenocepacia­lung­infections.­Infect­Immun.­
2004;­72:2850-2857.­DOI:10.1128/IAI.72.5.2850-2857.2004.
[128]­ Høiby­ N,­ Ciofu­ O,­ Bjarnsholt­ T.­ Pseudomonas aeruginosa­ biofilms­ in­ cystic­ fibrosis.­
Future­Microbiol.­2010;­5(11):1663-1674.­DOI:10.2217/fmb.10.125.
[129]­ Imperi­F,­Tiburzi­F,­Visca­P.­Molecular­basis­of­pyoverdine­siderophore­recycling­in­
Pseudomonas aeruginosa.­ Proc­Natl­Acad­ Sci.­ 2009;­ 106(48):20440-20445.­DOI:10.1073/
pnas.0908760106.
[130]­ Nikaido­ H,­ Pagès­ J-M.­ Broad-specificity­ efflux­ pumps­ and­ their­ role­ in­ multidrug­
resistance­ of­ Gram-negative­ bacteria.­ FEMS­ Microbiol­ Rev.­ 2012;­ 36(2):340-363.­
DOI:10.1111/j.1574-6976.2011.00290.x.





complex­ bacteria.­ Antimicrob­ Agents­ Chemother.­ 2013;­ 57:2972-2980.­ DOI:10.1128/
AAC.00140-13.
[132]­ Leitão­JH,­Sousa­SA,­Cunha­MV,­Salgado­MJ,­Melo-Cristino­J,­Barreto­MC,­Sá-Correia­
I.­Variation­of­the­antimicrobial­susceptibility­profiles­of­Burkholderia cepacia complex 












[136]­ Aronoff­SC.­Outer­membrane­permeability­ in­Pseudomonas cepacia:­diminished­porin­
content­ in­ a­ beta-lactam-resistant­ mutant­ and­ in­ resistant­ cystic­ fibrosis­ isolates.­
Antimicrob­Agents­Chemother.­1988;­32:1636-1639.­DOI:10.1128/AAC.32.11.1636.






division­drug­efflux­transporters­of­Burkholderia cenocepacia in intrinsic antibiotic resis-
tance.­BMC­Microbiol.­2009;­9:1-11.­DOI:10.1186/1471-2180-9-200.
[140]­ Nair­BM,­Cheung­KJ,­Griffith­A,­Burns­JL.­Salicylate­induces­an­antibiotic­efflux­pump­





ance in Burkholderia cenocepacia­biofilms.­Antimicrob­Agents­Chemother.­2011;­55:1912-
1919.­DOI:10.1128/AAC.01571-10.
Progress in Understanding Cystic Fibrosis96
[143]­ Buroni­ S,­ Matthijs­ N,­ Spadaro­ F,­ et­ al.­ Differential­ roles­ of­ RND­ efflux­ pumps­ in­
antimicrobial­ drug­ resistance­ of­ sessile­ and­planktonic­Burkholderia cenocepacia­ cells.­
Antimicrob­Agents­Chemother.­2014;­58:7424-7429.­DOI:10.1128/AAC.03800-14.
[144]­ Tseng­SP,­Tsai­WC,­Liang­CY,­et­al.­The­contribution­of­antibiotic­ resistance­mecha-
nisms in clinical Burkholderia cepacia­ complex­ isolates:­ an­ emphasis­ on­ efflux­ pump­
activity.­PLoS­One.­2014;­9(8):e104986.­DOI:10.1371/journal.pone.0104986.
[145]­ Drevinek­P,­Holden­MTG,­Ge­Z,­et­al.­Gene­expression­changes­linked­to­antimicrobial­




Burkholderia cenocepacia­ flagella­ to­ infectivity­ and­ inflammation.­ Infect­ Immun.­ 2004;­
72:5126-5134.­DOI:10.1128/IAI.72.9.5126-5134.2004.
[147]­ Kumar­B,­Cardona­ST.­Synthetic­cystic­fibrosis­sputum­medium­regulates­flagellar­bio-
synthesis through the flhF gene in Burkholderia cenocepacia.­Front­Cell­Infect­Microbiol.­
2016;­6:65.­DOI:10.3389/fcimb.2016.00065.
[148]­ Kalferstova­L,­Kolar­M,­Fila­L,­Vavrova­ J,­Drevinek­P.­Gene­ expression­profiling­of­
Burkholderia cenocepacia­at­the­time­of­cepacia­syndrome:­loss­of­motility­as­a­marker­of­
poor­prognosis?­J­Clin­Microbiol.­2015;­53:1515-1522.­DOI:10.1128/JCM.03605-14.
[149]­ Lamothe­J,­Thyssen­S,­Valvano­MA.­Burkholderia cepacia complex isolates survive intra-











[153]­ Lamothe­ J,­ Valvano­ MA.­ Burkholderia cenocepacia-induced­ delay­ of­ acidification­ and­











[156]­ Regan­ KH,­ Bhatt­ J.­ Eradication­ therapy­ for­ Burkholderia cepacia complex in people 
with­ cystic­ fibrosis.­ Cochrane­ Database­ Syst­ Rev.­ 2014;­ 10:1-21.­ CD009876.­ DOI:10. 
1002/14651858.CD009876.pub2.
[157]­ Pradenas,­GA,­Ross­BN,­Torres­AG.­Burkholderia cepacia­Complex­Vaccines:­Where Do­
We­Go­from­here?­Vaccines.­2016;­4,­10:1-14.­doi:10.3390/vaccines4020010.
[158]­ Schwab­U,­Abdullah­LH,­Perlmutt­OS,­et­al.­Localization­of­Burkholderia cepacia com-






to chronic Pseudomonas aeruginosa­lung­infection­in­cystic­fibrosis­patients­is­predomi-




of­the­cystic­fibrosis­associated­pathogen­Burkholderia cepacia complex to lung epithelial 
cells­and­protect­mice­against­infection.­Infect­Immun.­2016;­84:1424-1437.­DOI:10.1128/
IAI.01248-15.
[162]­ Bertot­ GM,­ Restelli­MA,­ Galanternik­ L,­Aranibar­ Urey­ RC,­ Valvano­MA,­ Grinstein­
S.­ Nasal­ immunization­with­Burkholderia multivorans outer membrane proteins and 
the­mucosal­adjuvant­adamantylamide­dipeptide­confers­efficient­protection­against­
experimental­lung­infections­with­B. multivorans and B. cenocepacia.­Infect­Immun.­2007;­
75:2740-2752.­DOI:10.1128/IAI.01668-06.
[163]­ Makidon­PE,­Knowlton­ J,­Groom­JV,­Blanco­LP,­LiPuma­ JJ,­Bielinska­AU,­Baker­ JR,­
Jr.­Induction­of­immune­response­to­the­17­kDa­OMPA­Burkholderia cenocepacia poly-






Priebe­ GP.­ Targeting­ pan-resistant­ bacteria­ with­ antibodies­ to­ a­ broadly­ conserved­
surface­ polysaccharide­ expressed­during­ infection.­ J­ Infect­Dis.­ 2012;­ 205:1709-1718.­
DOI:10.1093/infdis/jis254.
Progress in Understanding Cystic Fibrosis98




[166]­ Sousa­ SA,­Morad­M,­ Feliciano­ JR,­ Pita­ T,­Nady­ S,­ El-Hennamy­RE,­Abdel-Rahman­
M,­Cavaco­J,­Pereira­L,­Barreto­C,­Leitão­JH.­The­Burkholderia cenocepacia­OmpA-like­
protein­ BCAL2958:­ identification,­ characterization,­ and­ detection­ of­ anti-BCAL2958­
antibodies in serum from B. cepacia­ complex-infected­Cystic­ Fibrosis­ patients.­AMB­
Express.­2016;­6(1):41.­DOI:10.1186/s13568-016-0212-1.
[167]­ Mariappan­V,­Vellasamy­KM,­Thimma­JS,­Hashim­OH,­and­Vadivelu­J.­Identification­
of immunogenic proteins from Burkholderia cepacia­secretome­using­proteomic­analysis.­
Vaccine.­2010;­28:1318-1324.­DOI:10.1016/j.vaccine.2009.11.027.
[168]­ Shinoy­M,­ Dennehy­ R,­ Coleman­ L,­ Carberry­ S,­ Schaffer­ K,­ Callaghan­M,­ Doyle­ S,­
McClean­S.­ Immunoproteomic­analysis­of­proteins­ expressed­by­ two­ related­patho-
gens,­ Burkholderia multivorans and Burkholderia cenocepacia,­ during­ human­ infection.­
PLoS­One.­2013;­8(11):e80796.­DOI:10.1371/journal.pone.0080796.
Burkholderia cepacia Complex Infections Among Cystic Fibrosis Patients: Perspectives and Challenges
http://dx.doi.org/10.5772/67712
99

